| Cedargate Healthcare | |
| 2350 Kanell Blvd, Poplar Bluff, Missouri 63901 | |
| (573) 785-0188 | |
| Name | Cedargate Healthcare |
|---|---|
| Location | 2350 Kanell Blvd, Poplar Bluff, Missouri |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 108 |
| Occupancy Rate | 41.67% |
| Medicare ID (CCN) | 265205 |
| Legal Business Name | Cedargate Healthcare Group Llc |
| Ownership Type | For Profit - Limited Liability Company |
| NPI Number | 1740684851 |
| Organization Name | CEDARGATE HEALTHCARE GROUP, LLC |
| Doing Business As | CEDARGATE HEALTHCARE |
| Address | 2350 Kanell Blvd, Poplar Bluff, MO 63901 |
| Phone Number | 573-785-0188 |
News Archive
When mum or dad puffs on a cigarette, their infants may inhale the resulting second-hand smoke. Now, scientists have detected cancer-causing chemicals associated with tobacco smoke in the urine of nearly half the babies of smoking parents.
CIVCO Medical Solutions is introducing RAD-GUIDE, a needle guidance solution for CT and Fluoroscopy, at RSNA 2011. RAD-GUIDE allows physicians a method for introducing needles under CT or Fluoroscopy by visualizing and adjusting planned punctures prior to needle entry.
Catalyst Health Solutions, Inc., a pharmacy benefit management company, today announced its financial results for the quarter ended June 30, 2010. The Company reported quarterly net income of $19.5 million, up 21% compared to $16.2 million in the prior year. Earnings per diluted share increased by $0.07 to $0.44 from $0.37. Revenue for the quarter ended June 30, 2010, grew by 24% to $890.1 million from $717.6 million in the prior year.
Oncolytics Biotech Inc. announced today that it has completed Phase I patient enrollment in its Phase I/II clinical trial to investigate the use of REOLYSIN(R) for patients with recurrent malignant gliomas (REO 007). The principal investigator is Dr. James Markert, Division Director of Neurosurgery, and Professor, Neurosurgery and Physiology, the University of Alabama at Birmingham.
› Verified 3 days ago
| NPI Number | 1790805018 |
| Organization Name | MIDWEST HEALTH CARE, LLC |
| Doing Business As | THE CEDARGATE |
| Address | 2350 Kanell Blvd, Poplar Bluff, MO 63901 |
| Phone Number | 573-785-0188 |
News Archive
When mum or dad puffs on a cigarette, their infants may inhale the resulting second-hand smoke. Now, scientists have detected cancer-causing chemicals associated with tobacco smoke in the urine of nearly half the babies of smoking parents.
CIVCO Medical Solutions is introducing RAD-GUIDE, a needle guidance solution for CT and Fluoroscopy, at RSNA 2011. RAD-GUIDE allows physicians a method for introducing needles under CT or Fluoroscopy by visualizing and adjusting planned punctures prior to needle entry.
Catalyst Health Solutions, Inc., a pharmacy benefit management company, today announced its financial results for the quarter ended June 30, 2010. The Company reported quarterly net income of $19.5 million, up 21% compared to $16.2 million in the prior year. Earnings per diluted share increased by $0.07 to $0.44 from $0.37. Revenue for the quarter ended June 30, 2010, grew by 24% to $890.1 million from $717.6 million in the prior year.
Oncolytics Biotech Inc. announced today that it has completed Phase I patient enrollment in its Phase I/II clinical trial to investigate the use of REOLYSIN(R) for patients with recurrent malignant gliomas (REO 007). The principal investigator is Dr. James Markert, Division Director of Neurosurgery, and Professor, Neurosurgery and Physiology, the University of Alabama at Birmingham.
› Verified 3 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
When mum or dad puffs on a cigarette, their infants may inhale the resulting second-hand smoke. Now, scientists have detected cancer-causing chemicals associated with tobacco smoke in the urine of nearly half the babies of smoking parents.
CIVCO Medical Solutions is introducing RAD-GUIDE, a needle guidance solution for CT and Fluoroscopy, at RSNA 2011. RAD-GUIDE allows physicians a method for introducing needles under CT or Fluoroscopy by visualizing and adjusting planned punctures prior to needle entry.
Catalyst Health Solutions, Inc., a pharmacy benefit management company, today announced its financial results for the quarter ended June 30, 2010. The Company reported quarterly net income of $19.5 million, up 21% compared to $16.2 million in the prior year. Earnings per diluted share increased by $0.07 to $0.44 from $0.37. Revenue for the quarter ended June 30, 2010, grew by 24% to $890.1 million from $717.6 million in the prior year.
Oncolytics Biotech Inc. announced today that it has completed Phase I patient enrollment in its Phase I/II clinical trial to investigate the use of REOLYSIN(R) for patients with recurrent malignant gliomas (REO 007). The principal investigator is Dr. James Markert, Division Director of Neurosurgery, and Professor, Neurosurgery and Physiology, the University of Alabama at Birmingham.
› Verified 3 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 9.36 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 9.36 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 30.3 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.14 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 4.68 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.22 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 71.67 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 19.16 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 50 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 20.13 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 19.89 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 4.17 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 92.34 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 68.81 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 68.93 | 82.93 |
News Archive
When mum or dad puffs on a cigarette, their infants may inhale the resulting second-hand smoke. Now, scientists have detected cancer-causing chemicals associated with tobacco smoke in the urine of nearly half the babies of smoking parents.
CIVCO Medical Solutions is introducing RAD-GUIDE, a needle guidance solution for CT and Fluoroscopy, at RSNA 2011. RAD-GUIDE allows physicians a method for introducing needles under CT or Fluoroscopy by visualizing and adjusting planned punctures prior to needle entry.
Catalyst Health Solutions, Inc., a pharmacy benefit management company, today announced its financial results for the quarter ended June 30, 2010. The Company reported quarterly net income of $19.5 million, up 21% compared to $16.2 million in the prior year. Earnings per diluted share increased by $0.07 to $0.44 from $0.37. Revenue for the quarter ended June 30, 2010, grew by 24% to $890.1 million from $717.6 million in the prior year.
Oncolytics Biotech Inc. announced today that it has completed Phase I patient enrollment in its Phase I/II clinical trial to investigate the use of REOLYSIN(R) for patients with recurrent malignant gliomas (REO 007). The principal investigator is Dr. James Markert, Division Director of Neurosurgery, and Professor, Neurosurgery and Physiology, the University of Alabama at Birmingham.
› Verified 3 days ago
Westwood Hills Health & Rehabilitation Center Location: 3100 Warrior Lane, Poplar Bluff, Missouri 63901 Phone: (573) 785-0851 | |
Mark Twain Caring Center Location: 3001 May Street, Poplar Bluff, Missouri 63901 Phone: (573) 686-6999 | |